Cargando…
Clinical quantification of the integrin αvβ6 by [(18)F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL Study)
PURPOSE: The RGD-integrin, αvβ6, plays a role in the pathogenesis of pulmonary fibrosis through activation of transforming growth factor beta (TGFβ). This study sought to quantify expression of αvβ6 in the lungs of healthy humans and subjects with pulmonary fibrosis using the αvβ6-selective [(18)F]F...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7075837/ https://www.ncbi.nlm.nih.gov/pubmed/31814068 http://dx.doi.org/10.1007/s00259-019-04586-z |
_version_ | 1783507096892866560 |
---|---|
author | Lukey, Pauline T. Coello, Christopher Gunn, Roger Parker, Christine Wilson, Frederick J. Saleem, Azeem Garman, Nadia Costa, Maria Kendrick, Stuart Onega, Mayca Kang’ombe, Arthur R. Listanco, Allan Davies, James Ramada-Magalhaes, Joaquim Moz, Sara Fahy, William A. Maher, Toby M. Jenkins, Gisli Passchier, Jan Marshall, Richard P. |
author_facet | Lukey, Pauline T. Coello, Christopher Gunn, Roger Parker, Christine Wilson, Frederick J. Saleem, Azeem Garman, Nadia Costa, Maria Kendrick, Stuart Onega, Mayca Kang’ombe, Arthur R. Listanco, Allan Davies, James Ramada-Magalhaes, Joaquim Moz, Sara Fahy, William A. Maher, Toby M. Jenkins, Gisli Passchier, Jan Marshall, Richard P. |
author_sort | Lukey, Pauline T. |
collection | PubMed |
description | PURPOSE: The RGD-integrin, αvβ6, plays a role in the pathogenesis of pulmonary fibrosis through activation of transforming growth factor beta (TGFβ). This study sought to quantify expression of αvβ6 in the lungs of healthy humans and subjects with pulmonary fibrosis using the αvβ6-selective [(18)F]FB-A20FMDV2 PET ligand. METHODS: [(18)F]FB-A20FMDV2 PET/CT scans were performed in healthy subjects and those with fibrotic lung disease. Standard uptake values (SUV) and volume of distribution (V(T)) were used to quantify αvβ6 expression. In subjects with fibrotic lung disease, qualitative assessment of the relationship between αvβ6 expression and the distribution of fibrosis on high resolution computed tomography was conducted. RESULTS: A total of 15 participants (6 healthy, 7 with idiopathic pulmonary fibrosis (IPF) and 2 with connective tissue disease (CTD) associated PF) were enrolled. V(T) and SUV of [(18)F]FB-A20FMDV2 were increased in the lungs of subjects with pulmonary fibrosis (PF) compared with healthy subjects. Geometric mean V(T) (95% CI) was 0.88 (0.60, 1.29) mL/cm(3) for healthy subjects, and 1.40 (1.22, 1.61) mL/cm(3) for subjects with IPF; and SUV was 0.54 (0.36, 0.81) g/mL for healthy subjects and 1.03 (0.86, 1.22) g/mL for subjects with IPF. The IPF/healthy V(T) ratio (geometric mean, (95% CI of ratio)) was 1.59 (1.09, 2.32) (probability ratio > 1 = 0.988)) and the SUV ratio was 1.91 (1.27, 2.87) (probability ratio > 1 = 0.996). Increased uptake of [(18)F]FB-A20FMDV2 in PF was predominantly confined to fibrotic areas. [(18)F]FB-A20FMDV2 measurements were reproducible at an interval of 2 weeks. [(18)F]FB-A20FMDV2 was safe and well tolerated. CONCLUSIONS: Lung uptake of [(18)F]FB-A20FMDV2, a measure of expression of the integrin αvβ6, was markedly increased in subjects with PF compared with healthy subjects. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00259-019-04586-z) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-7075837 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-70758372020-03-23 Clinical quantification of the integrin αvβ6 by [(18)F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL Study) Lukey, Pauline T. Coello, Christopher Gunn, Roger Parker, Christine Wilson, Frederick J. Saleem, Azeem Garman, Nadia Costa, Maria Kendrick, Stuart Onega, Mayca Kang’ombe, Arthur R. Listanco, Allan Davies, James Ramada-Magalhaes, Joaquim Moz, Sara Fahy, William A. Maher, Toby M. Jenkins, Gisli Passchier, Jan Marshall, Richard P. Eur J Nucl Med Mol Imaging Original Article PURPOSE: The RGD-integrin, αvβ6, plays a role in the pathogenesis of pulmonary fibrosis through activation of transforming growth factor beta (TGFβ). This study sought to quantify expression of αvβ6 in the lungs of healthy humans and subjects with pulmonary fibrosis using the αvβ6-selective [(18)F]FB-A20FMDV2 PET ligand. METHODS: [(18)F]FB-A20FMDV2 PET/CT scans were performed in healthy subjects and those with fibrotic lung disease. Standard uptake values (SUV) and volume of distribution (V(T)) were used to quantify αvβ6 expression. In subjects with fibrotic lung disease, qualitative assessment of the relationship between αvβ6 expression and the distribution of fibrosis on high resolution computed tomography was conducted. RESULTS: A total of 15 participants (6 healthy, 7 with idiopathic pulmonary fibrosis (IPF) and 2 with connective tissue disease (CTD) associated PF) were enrolled. V(T) and SUV of [(18)F]FB-A20FMDV2 were increased in the lungs of subjects with pulmonary fibrosis (PF) compared with healthy subjects. Geometric mean V(T) (95% CI) was 0.88 (0.60, 1.29) mL/cm(3) for healthy subjects, and 1.40 (1.22, 1.61) mL/cm(3) for subjects with IPF; and SUV was 0.54 (0.36, 0.81) g/mL for healthy subjects and 1.03 (0.86, 1.22) g/mL for subjects with IPF. The IPF/healthy V(T) ratio (geometric mean, (95% CI of ratio)) was 1.59 (1.09, 2.32) (probability ratio > 1 = 0.988)) and the SUV ratio was 1.91 (1.27, 2.87) (probability ratio > 1 = 0.996). Increased uptake of [(18)F]FB-A20FMDV2 in PF was predominantly confined to fibrotic areas. [(18)F]FB-A20FMDV2 measurements were reproducible at an interval of 2 weeks. [(18)F]FB-A20FMDV2 was safe and well tolerated. CONCLUSIONS: Lung uptake of [(18)F]FB-A20FMDV2, a measure of expression of the integrin αvβ6, was markedly increased in subjects with PF compared with healthy subjects. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00259-019-04586-z) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2019-12-09 2020 /pmc/articles/PMC7075837/ /pubmed/31814068 http://dx.doi.org/10.1007/s00259-019-04586-z Text en © The Author(s) 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Article Lukey, Pauline T. Coello, Christopher Gunn, Roger Parker, Christine Wilson, Frederick J. Saleem, Azeem Garman, Nadia Costa, Maria Kendrick, Stuart Onega, Mayca Kang’ombe, Arthur R. Listanco, Allan Davies, James Ramada-Magalhaes, Joaquim Moz, Sara Fahy, William A. Maher, Toby M. Jenkins, Gisli Passchier, Jan Marshall, Richard P. Clinical quantification of the integrin αvβ6 by [(18)F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL Study) |
title | Clinical quantification of the integrin αvβ6 by [(18)F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL Study) |
title_full | Clinical quantification of the integrin αvβ6 by [(18)F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL Study) |
title_fullStr | Clinical quantification of the integrin αvβ6 by [(18)F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL Study) |
title_full_unstemmed | Clinical quantification of the integrin αvβ6 by [(18)F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL Study) |
title_short | Clinical quantification of the integrin αvβ6 by [(18)F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL Study) |
title_sort | clinical quantification of the integrin αvβ6 by [(18)f]fb-a20fmdv2 positron emission tomography in healthy and fibrotic human lung (petal study) |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7075837/ https://www.ncbi.nlm.nih.gov/pubmed/31814068 http://dx.doi.org/10.1007/s00259-019-04586-z |
work_keys_str_mv | AT lukeypaulinet clinicalquantificationoftheintegrinavb6by18ffba20fmdv2positronemissiontomographyinhealthyandfibrotichumanlungpetalstudy AT coellochristopher clinicalquantificationoftheintegrinavb6by18ffba20fmdv2positronemissiontomographyinhealthyandfibrotichumanlungpetalstudy AT gunnroger clinicalquantificationoftheintegrinavb6by18ffba20fmdv2positronemissiontomographyinhealthyandfibrotichumanlungpetalstudy AT parkerchristine clinicalquantificationoftheintegrinavb6by18ffba20fmdv2positronemissiontomographyinhealthyandfibrotichumanlungpetalstudy AT wilsonfrederickj clinicalquantificationoftheintegrinavb6by18ffba20fmdv2positronemissiontomographyinhealthyandfibrotichumanlungpetalstudy AT saleemazeem clinicalquantificationoftheintegrinavb6by18ffba20fmdv2positronemissiontomographyinhealthyandfibrotichumanlungpetalstudy AT garmannadia clinicalquantificationoftheintegrinavb6by18ffba20fmdv2positronemissiontomographyinhealthyandfibrotichumanlungpetalstudy AT costamaria clinicalquantificationoftheintegrinavb6by18ffba20fmdv2positronemissiontomographyinhealthyandfibrotichumanlungpetalstudy AT kendrickstuart clinicalquantificationoftheintegrinavb6by18ffba20fmdv2positronemissiontomographyinhealthyandfibrotichumanlungpetalstudy AT onegamayca clinicalquantificationoftheintegrinavb6by18ffba20fmdv2positronemissiontomographyinhealthyandfibrotichumanlungpetalstudy AT kangombearthurr clinicalquantificationoftheintegrinavb6by18ffba20fmdv2positronemissiontomographyinhealthyandfibrotichumanlungpetalstudy AT listancoallan clinicalquantificationoftheintegrinavb6by18ffba20fmdv2positronemissiontomographyinhealthyandfibrotichumanlungpetalstudy AT daviesjames clinicalquantificationoftheintegrinavb6by18ffba20fmdv2positronemissiontomographyinhealthyandfibrotichumanlungpetalstudy AT ramadamagalhaesjoaquim clinicalquantificationoftheintegrinavb6by18ffba20fmdv2positronemissiontomographyinhealthyandfibrotichumanlungpetalstudy AT mozsara clinicalquantificationoftheintegrinavb6by18ffba20fmdv2positronemissiontomographyinhealthyandfibrotichumanlungpetalstudy AT fahywilliama clinicalquantificationoftheintegrinavb6by18ffba20fmdv2positronemissiontomographyinhealthyandfibrotichumanlungpetalstudy AT mahertobym clinicalquantificationoftheintegrinavb6by18ffba20fmdv2positronemissiontomographyinhealthyandfibrotichumanlungpetalstudy AT jenkinsgisli clinicalquantificationoftheintegrinavb6by18ffba20fmdv2positronemissiontomographyinhealthyandfibrotichumanlungpetalstudy AT passchierjan clinicalquantificationoftheintegrinavb6by18ffba20fmdv2positronemissiontomographyinhealthyandfibrotichumanlungpetalstudy AT marshallrichardp clinicalquantificationoftheintegrinavb6by18ffba20fmdv2positronemissiontomographyinhealthyandfibrotichumanlungpetalstudy |